DB-289 Immtech International.
DB-289, an oral diamidoxime prodrug of DB-75 from the University of North Carolina, Georgia State University, Auburn University and Duke University, is being developed by Immtech International as a potential treatment for Pneumocystis carinii pneumonia (PCP), tuberculosis, trypanosomiasis and malaria.
Yeates
Clive
C
6 Dudley Hill Close, Welwyn, Herts, AL6 0QQ, UK. cly@welwyn11.freeserve.co.uk
D000818:Animals; D000962:Antimalarials / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001550:Benzamidines / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D011355:Prodrugs / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013329:Structure-Activity Relationship; D014344:Trypanocidal Agents / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use
D000962:Antimalarials; D000981:Antiprotozoal Agents; D000995:Antitubercular Agents; D001550:Benzamidines; D011355:Prodrugs; D014344:Trypanocidal Agents; C033286:furamidine; C458513:pafuramidine